Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: An immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 629-639

  Miettinen, Markku ^a   Rikala, Maarit Sarlomo ^b   Rys, Janusz ^c   Lasota, Jerzy ^a   Wang, Zeng Feng ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

adult tissue; angiosarcoma; endothelial cell; fetal tis sue; Kaposi sarcoma; malignant meso thelioma; mesothelial cell; VEGFR2

Indexed keywords

TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

ANIMAL EMBRYO; ARTICLE; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; METABOLISM; NEOPLASM; PATHOLOGY; PRENATAL DEVELOPMENT; TISSUE MICROARRAY; VASCULAR ENDOTHELIUM; VASCULAR TUMOR;

EMBRYO, MAMMALIAN; ENDOTHELIUM, VASCULAR; FEMALE; GESTATIONAL AGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR NEOPLASMS;

EID: 84862822760     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318243555b     Document Type: Article

References (37)

1. Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119:227-235.
2. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175-7179.
3. Brown LF, Tognazzi K, Dvorak HF, et al. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 1996;148:1065-1074.
4. Carlevaro MF, Cermelli S, Cancedda R, et al. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during enchondral bone formation. J Cell Sci. 2000;113:59-69.
5. Cortés F, Debacker C, Peault B, et al. Differential expression of KDR/VEGFR-2 and CD34 during mesoderm development of the early human embryo. Mech Dev. 1999;83:161-164.
6. Dev IK, Dornsife RE, Hopper TM, et al. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. Brit J Cancer. 2004;91:1391-1398.
7. De Young BR, Wick MR, Fitzgibbon JF, et al. CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl Immunohistochem. 1993;1:97-100.
8. Dominguez-Malagon H, Valdez AM, Moran CA, et al. Germ cell tumors with sarcomatous components: a clinicopathological and immunohistochemical study of 46 cases. Am J Surg Pathol. 2007; 31:1356-1362.
9. Donnem T, Al-Shibli K, Andersen S, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116:4318-4325.
10. Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for antiangiogenic therapy. Eur J Cancer. 2006;42:112-117.
11. Farkkila A, Anttonen M, Pociuviene J, et al. Vascular endothelial growth factor and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol. 2011;64:115-122.
12. Ghosh S, Sullivan CAW, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol. 2008;39:1835-1843.
13. Gratzinger D, Advani R, Zhao S, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Brit J Hematol. 2009;148:235-244.
14. Huang J, Zhang X, Tang Q, et al. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol. 2011;64:343-348.
15. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGF1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008;14:1236-1246.
16. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40 a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434-440.
17. Korpanty G, Sullivan LA, Smyth E, et al. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol. 2010;2010:652320.
18. Mehnert JM, McCarthy MM, Jilaveanu L, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010;41:375-384.
19. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am J Surg Pathol. 2001;25:1167-1173.
20. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Yantigens- evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand's factor. Mod Pathol. 1994;7:82-90.
21. Miettinen M,Miettinen M, Wang ZF, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35:432-441.
22. Miettinen M, Sarlomo-Rikala M, Wang ZF. Claudin 5 as immunohistochemical marker for angiosarcoma and hemangioendotheliomas. Am J Surg Pathol. 2011;35:1848-1856.
23. Miettinen M, Wang ZF. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am J Surg Pathol. (In press).
24. Neuchrist C, Erovic BM, Handisurya A, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope. 2001;111:1834-1841.
25. Nutt JE, O'Toole K, Gonzalez D, et al. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. Eur J Cancer. 2009;45:1684-1691.
26. ParkMS, Ravi V, AraujoDM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fibrous tumor. Curr Opin Oncol. 2010;22:351-355.
27. Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic nevi and cutaneous melanomas. Melanoma Res. 2005;15:39-43.
28. Rydén L, Linderholm B, Nielsen NH, et al. Tumor specific VEGFA and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat. 2003;82:147-154.
29. Sato H, Takeda Y. VEGFR2 expression and relationship between tumor neovascularization and histologic characteristics in oral squamous cell carcinoma. J Oral Sci. 2009;4:551-557.
30. Seto H, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage 1 non-small-cell lung cancer. Lung Cancer. 2006;53:91-96.
31. Schimanski CC, Zimmermann T, Schmidtmann I, et al. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRa in colorectal cancer. Int J Colorect Dis. 2010;25:181-186.
32. Shibuya M. Vascular endothelial growth factor (VEGF)-receptor 2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006;13:63-69.
33. Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 2010;16:3548-3561.
34. Tanigawa N, Amaya H, Matsumura M, et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997;15:826-832.
35. Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosom Cancer. 2002;33:295-303.
36. Xia G, Kumar SR, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006;175:1245-1252.
37. Yakes FM, Chen J, Tan J, et al. Cabozanitib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10: 2298-2308.